Phage composition

A phage composition targeting Serratia marcescens, Klebsiella pneumoniae, and Pseudomonas aeruginosa bacteria through specific nucleic acid hybridization effectively suppresses bacterial growth and biofilm formation, offering a promising alternative to antibiotics for treating antimicrobial-resistant infections.

WO2025242868A1PCT designated stage Publication Date: 2025-11-27HELMHOLTZ ZENT MUENCHEN DEUT FORSCHUNGSZENTRUM FUER GESUNDHEIT & UMWELT (GMBH)
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2025/064275
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-23
Filing Date
2025-05-23
Publication Date
2025-11-27

AI Technical Summary

Technical Problem

The spread of multi-drug resistant bacteria such as Serratia marcescens, Klebsiella pneumoniae, and Pseudomonas aeruginosa poses a significant threat due to their resistance to current antibiotics, leading to infections in immunocompromised individuals and high morbidity and mortality rates, necessitating an alternative therapeutic approach.

Method used

A composition of isolated phages that specifically target and infect these bacteria, suppressing their growth by replicating within host cells and lysing them, while also mitigating biofilm formation, utilizing nucleic acid sequences that hybridize under stringent conditions to signature sequences encoding specific amino acid sequences.

Benefits of technology

The phage composition effectively suppresses bacterial growth and biofilm formation, providing a viable alternative to antibiotics by efficiently eliminating antimicrobial-resistant strains of Serratia marcescens, Klebsiella pneumoniae, and Pseudomonas aeruginosa, thereby reducing infection severity and mortality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000081_0001
    Figure IMGF000081_0001
  • Figure IMGF000082_0001
    Figure IMGF000082_0001
  • Figure IMGF000083_0001
    Figure IMGF000083_0001
Patent Text Reader

Abstract

The present invention relates to a composition comprising different isolated phages, wherein the phages comprise a nucleic acid being part of their genome, which hybridizes under stringent conditions to a particular signature sequence or its complementary sequence hereto comprising a nucleic acid sequence encoding their corresponding amino acid sequences, wherein the phages are capable of suppressing growth of Serratia marcescens, Klebsiella pneumoniae, and Pseudomonas aeruginosa such that OD600 is not higher than 0.5. The present invention also relates to a pharmaceutical composition comprising said composition, and to said composition or said pharmaceutical composition for use in therapy as well as for use in a method of treating or preventing a bacterial infection caused by at least any one of S. marcescens, K. pneumonia or P. aeruginosa. Additionally, the present invention relates to kits and to a method of preparing said composition comprising isolated phages and a composition comprising isolated phages obtainable or obtained by said method.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same

    EP0302175A2

  • Modified nucleotides and methods of preparing and using same

    US4711955A

  • Pteridine nucleotide analogs as fluorescent DNA probes

    US5525711A

  • Nuclease stable and binding competent oligomers and methods for their use

    US5792608A

  • Serratia marcescens bacteriophage and medical application thereof

    CN113186169A